Magnesium Sulfuricum Bbp (Magnesium Sulfate Heptahydrate)

Magnesium sulfate heptahydrate releases magnesium ions that serve as cofactors for many enzymatic reactions, stabilize cell membranes, and oppose calcium‑mediated excitability. By increasing extracellular magnesium, it helps normalize nerve and muscle activity, supports cardiac electrical stability, and corrects electrolyte imbalances.

The dose of Magnesium Sulfuricum Bbp is determined by the prescribing clinician based on the patient’s clinical condition, serum magnesium level, renal function, and route of administration. Healthcare professionals calculate the appropriate amount and infusion rate for each individual case.

Magnesium sulfate is classified as a pregnancy category that requires a risk‑benefit assessment. It is commonly used for eclampsia under medical supervision, but the prescriber must evaluate maternal and fetal safety. Limited data are available for breastfeeding, so clinicians should consider potential exposure to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Magnesium Sulfuricum Bbp provides magnesium as a sterile injectable solution, allowing rapid intravenous or intramuscular delivery, which is advantageous in acute settings such as eclampsia or cardiac arrhythmias. Oral magnesium salts are slower to act and may have lower bioavailability, making injectables preferred for urgent correction.

The product should be stored at ambient temperature, protected from moisture and direct sunlight. Keep the vial in its original packaging until use, and inspect for particulate matter or discoloration before administration. Follow standard aseptic techniques when preparing the injection.

Magnesium Sulfuricum Bbp is administered by a qualified healthcare professional via intramuscular, intravenous, or subcutaneous injection. The route, infusion rate, and total dose are selected by the prescriber according to the indication, patient weight, and serum magnesium levels.

Serious risks include hypermagnesemia, which can cause respiratory depression, severe hypotension, cardiac arrest, and loss of deep tendon reflexes. Anaphylactic reactions are rare but possible. Continuous monitoring of vital signs and serum magnesium is essential during high‑dose or rapid infusions.

Patients with severe renal failure, uncontrolled heart block, or known hypersensitivity to magnesium sulfate should not receive this product. Caution is also advised for individuals on concurrent calcium therapy or those receiving other magnesium‑containing medications without appropriate monitoring.